AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

LAMIVUDINE + STAVUDINE + NEVIRAPINE

10 registrations across 1 African market— 0 active

Markets with LAMIVUDINE + STAVUDINE + NEVIRAPINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
NEVILAST-30 150MG/30MG/200MG TABLET
TABLET
🇲🇼MalawiexpiredJun 2016
TRIOMUNE-BABY COMBINATION PRODUCT DISPERSIBLE TABLET
DISPERSIBLE TABLET
🇲🇼MalawiexpiredJun 2013
TRIOMUNE_JUNIOR COMBINATION PRODUCT DISPERSIBLE TABLET
DISPERSIBLE TABLET
🇲🇼MalawiexpiredJun 2013
NEVILAST-30 COMBINATION PRODUCT TABLET
TABLET
🇲🇼MalawiexpiredJun 2012
LAMIVUDINE_STAVUDINE_NEVIRAPINE 150/30/200MG TABLET
TABLET
🇲🇼MalawiexpiredJun 2011
LAMIVUDINE_STAVUDINE_NEVIRAPINE 60/12/100MG DISPERSIBLE TABLET
DISPERSIBLE TABLET
🇲🇼MalawiexpiredJun 2011
LAMIVUDINE+STAVUDINE+NEVIRAPINE 30/6/50MG DISPERSIBLE TABLET
DISPERSIBLE TABLET
🇲🇼MalawiexpiredJun 2011
NEVILAST-40 COMBINATION PRODUCT TABLET
TABLET
🇲🇼MalawiexpiredJun 2010
NEVILAST-40 150MG/40MG/200MG TABLET
TABLET
🇲🇼MalawiexpiredJun 2010
TRIOMUNE-40 COMBINATION PRODUCT TABLET
TABLET
🇲🇼MalawiexpiredJun 2010

LAMIVUDINE + STAVUDINE + NEVIRAPINE in Africa — Regulatory Overview

LAMIVUDINE + STAVUDINE + NEVIRAPINE is registered across 1 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 0 (0%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.